Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.53
(0.36%)
USD 0.53
(0.36%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 38.99 Million USD | -24.61% |
| 2022 | 51.72 Million USD | -38.16% |
| 2021 | 83.64 Million USD | 552.37% |
| 2020 | 12.82 Million USD | -9.9% |
| 2019 | 14.23 Million USD | 51.17% |
| 2018 | 9.41 Million USD | 4.86% |
| 2017 | 8.97 Million USD | -25.58% |
| 2016 | 12.06 Million USD | -33.76% |
| 2015 | 18.21 Million USD | 49.55% |
| 2014 | 12.17 Million USD | -21.27% |
| 2013 | 15.46 Million USD | 183.59% |
| 2012 | 5.45 Million USD | 24.77% |
| 2011 | 4.37 Million USD | 13.63% |
| 2010 | 3.84 Million USD | 61.23% |
| 2009 | 2.38 Million USD | -55.67% |
| 2008 | 5.38 Million USD | 67.07% |
| 2007 | 3.22 Million USD | 28.05% |
| 2006 | 2.51 Million USD | 16.72% |
| 2005 | 2.15 Million USD | 83.15% |
| 2004 | 1.17 Million USD | -66.4% |
| 2003 | 3.5 Million USD | 31.3% |
| 2002 | 2.66 Million USD | 30.72% |
| 2001 | 2.04 Million USD | 467.19% |
| 2000 | 359.74 Thousand USD | -39.59% |
| 1999 | 595.51 Thousand USD | 48.88% |
| 1998 | 400 Thousand USD | -77.78% |
| 1997 | 1.8 Million USD | 800.0% |
| 1996 | 200 Thousand USD | -50.0% |
| 1995 | 400 Thousand USD | 300.0% |
| 1994 | 100 Thousand USD | 0.0% |
| 1993 | 100 Thousand USD | -50.0% |
| 1992 | 200 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 37.49 Million USD | -3.85% |
| 2024 Q2 | 35.92 Million USD | -4.18% |
| 2023 Q2 | 40.43 Million USD | -8.51% |
| 2023 Q3 | 39.49 Million USD | -2.32% |
| 2023 FY | 38.99 Million USD | -24.61% |
| 2023 Q4 | 38.99 Million USD | -1.26% |
| 2023 Q1 | 44.19 Million USD | -14.57% |
| 2022 Q3 | 53.59 Million USD | -1.52% |
| 2022 FY | 51.72 Million USD | -38.16% |
| 2022 Q2 | 54.42 Million USD | -8.23% |
| 2022 Q1 | 59.3 Million USD | -29.1% |
| 2022 Q4 | 51.72 Million USD | -3.48% |
| 2021 FY | 83.64 Million USD | 552.37% |
| 2021 Q1 | 11.35 Million USD | -11.42% |
| 2021 Q4 | 83.64 Million USD | 619.67% |
| 2021 Q3 | 11.62 Million USD | 4.21% |
| 2021 Q2 | 11.15 Million USD | -1.8% |
| 2020 FY | 12.82 Million USD | -9.9% |
| 2020 Q3 | 12.9 Million USD | -10.29% |
| 2020 Q2 | 14.38 Million USD | 1.86% |
| 2020 Q1 | 14.12 Million USD | -0.75% |
| 2020 Q4 | 12.82 Million USD | -0.65% |
| 2019 Q3 | 17.45 Million USD | -12.41% |
| 2019 Q4 | 14.23 Million USD | -18.49% |
| 2019 Q2 | 19.93 Million USD | -11.33% |
| 2019 FY | 14.23 Million USD | 51.17% |
| 2019 Q1 | 22.47 Million USD | 138.78% |
| 2018 Q2 | 7.5 Million USD | -5.54% |
| 2018 Q4 | 9.41 Million USD | 44.41% |
| 2018 Q3 | 6.51 Million USD | -13.08% |
| 2018 Q1 | 7.94 Million USD | -11.56% |
| 2018 FY | 9.41 Million USD | 4.86% |
| 2017 Q1 | 15.51 Million USD | 28.64% |
| 2017 Q2 | 15.16 Million USD | -2.26% |
| 2017 Q3 | 12.88 Million USD | -15.08% |
| 2017 Q4 | 8.97 Million USD | -30.3% |
| 2017 FY | 8.97 Million USD | -25.58% |
| 2016 Q2 | 10.27 Million USD | -49.93% |
| 2016 FY | 12.06 Million USD | -33.76% |
| 2016 Q1 | 20.52 Million USD | 12.68% |
| 2016 Q3 | 11.33 Million USD | 10.3% |
| 2016 Q4 | 12.06 Million USD | 6.45% |
| 2015 Q4 | 18.21 Million USD | 14.37% |
| 2015 FY | 18.21 Million USD | 49.55% |
| 2015 Q1 | 12.19 Million USD | 0.11% |
| 2015 Q2 | 14.65 Million USD | 20.24% |
| 2015 Q3 | 15.92 Million USD | 8.64% |
| 2014 Q3 | 16.7 Million USD | -13.92% |
| 2014 FY | 12.17 Million USD | -21.27% |
| 2014 Q2 | 19.4 Million USD | 54.15% |
| 2014 Q1 | 12.58 Million USD | -18.63% |
| 2014 Q4 | 12.17 Million USD | -27.08% |
| 2013 Q4 | 15.46 Million USD | 181.98% |
| 2013 Q1 | 5.31 Million USD | -2.56% |
| 2013 Q2 | 5.37 Million USD | 1.16% |
| 2013 FY | 15.46 Million USD | 183.59% |
| 2013 Q3 | 5.48 Million USD | 2.02% |
| 2012 Q2 | 4.08 Million USD | 29.88% |
| 2012 Q4 | 5.45 Million USD | 49.07% |
| 2012 Q1 | 3.14 Million USD | -28.01% |
| 2012 FY | 5.45 Million USD | 24.77% |
| 2012 Q3 | 3.65 Million USD | -10.48% |
| 2011 FY | 4.37 Million USD | 13.63% |
| 2011 Q3 | 3.95 Million USD | -13.71% |
| 2011 Q4 | 4.37 Million USD | 10.42% |
| 2011 Q1 | 4.08 Million USD | 6.19% |
| 2011 Q2 | 4.58 Million USD | 12.32% |
| 2010 Q1 | 2.28 Million USD | -4.24% |
| 2010 FY | 3.84 Million USD | 61.23% |
| 2010 Q4 | 3.84 Million USD | 61.32% |
| 2010 Q3 | 2.38 Million USD | -4.77% |
| 2010 Q2 | 2.5 Million USD | 9.59% |
| 2009 Q4 | 2.38 Million USD | -53.39% |
| 2009 FY | 2.38 Million USD | -55.67% |
| 2009 Q1 | 6.63 Million USD | 23.29% |
| 2009 Q2 | 6.61 Million USD | -0.37% |
| 2009 Q3 | 5.11 Million USD | -22.56% |
| 2008 Q2 | 4.53 Million USD | 15.83% |
| 2008 FY | 5.38 Million USD | 67.07% |
| 2008 Q1 | 3.91 Million USD | 21.41% |
| 2008 Q4 | 5.38 Million USD | -7.94% |
| 2008 Q3 | 5.84 Million USD | 29.05% |
| 2007 Q1 | 2.73 Million USD | 8.88% |
| 2007 FY | 3.22 Million USD | 28.05% |
| 2007 Q4 | 3.22 Million USD | 10.84% |
| 2007 Q3 | 2.9 Million USD | 2.44% |
| 2007 Q2 | 2.83 Million USD | 3.58% |
| 2006 Q1 | 2.38 Million USD | 10.73% |
| 2006 FY | 2.51 Million USD | 16.72% |
| 2006 Q4 | 2.51 Million USD | 4.84% |
| 2006 Q3 | 2.39 Million USD | 1.44% |
| 2006 Q2 | 2.36 Million USD | -0.89% |
| 2005 Q2 | 1.46 Million USD | 27.32% |
| 2005 FY | 2.15 Million USD | 83.15% |
| 2005 Q1 | 1.15 Million USD | -1.92% |
| 2005 Q4 | 2.15 Million USD | 28.08% |
| 2005 Q3 | 1.68 Million USD | 14.51% |
| 2004 FY | 1.17 Million USD | -66.4% |
| 2004 Q4 | 1.17 Million USD | 55.74% |
| 2004 Q3 | 755.6 Thousand USD | -8.69% |
| 2004 Q2 | 827.49 Thousand USD | 42.93% |
| 2004 Q1 | 578.94 Thousand USD | -83.47% |
| 2003 FY | 3.5 Million USD | 31.3% |
| 2003 Q2 | 3 Million USD | -5.78% |
| 2003 Q4 | 3.5 Million USD | 12.04% |
| 2003 Q1 | 3.18 Million USD | 19.51% |
| 2003 Q3 | 3.12 Million USD | 4.08% |
| 2002 FY | 2.66 Million USD | 30.72% |
| 2002 Q2 | 2.28 Million USD | 13.37% |
| 2002 Q1 | 2.01 Million USD | -1.29% |
| 2002 Q3 | 2.32 Million USD | 1.61% |
| 2002 Q4 | 2.66 Million USD | 14.95% |
| 2001 Q3 | 3.45 Million USD | 315.65% |
| 2001 Q1 | 136.43 Thousand USD | -62.08% |
| 2001 FY | 2.04 Million USD | 467.19% |
| 2001 Q4 | 2.04 Million USD | -40.89% |
| 2001 Q2 | 830.56 Thousand USD | 508.77% |
| 2000 Q3 | 113.91 Thousand USD | -63.04% |
| 2000 Q2 | 308.17 Thousand USD | 141.98% |
| 2000 Q1 | 127.35 Thousand USD | -78.61% |
| 2000 FY | 359.74 Thousand USD | -39.59% |
| 2000 Q4 | 359.74 Thousand USD | 215.8% |
| 1999 Q2 | 300 Thousand USD | -25.0% |
| 1999 Q3 | 500 Thousand USD | 66.67% |
| 1999 Q1 | 400 Thousand USD | 0.0% |
| 1999 Q4 | 595.51 Thousand USD | 19.1% |
| 1999 FY | 595.51 Thousand USD | 48.88% |
| 1998 Q2 | 600 Thousand USD | -25.0% |
| 1998 Q3 | 500 Thousand USD | -16.67% |
| 1998 Q1 | 800 Thousand USD | -20.0% |
| 1998 FY | 400 Thousand USD | -77.78% |
| 1997 Q3 | 1.6 Million USD | -11.11% |
| 1997 Q4 | 1 Million USD | -37.5% |
| 1997 FY | 1.8 Million USD | 800.0% |
| 1997 Q1 | 100 Thousand USD | -66.67% |
| 1997 Q2 | 1.8 Million USD | 1700.0% |
| 1996 Q3 | 100 Thousand USD | -50.0% |
| 1996 FY | 200 Thousand USD | -50.0% |
| 1996 Q4 | 300 Thousand USD | 200.0% |
| 1996 Q2 | 200 Thousand USD | 0.0% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| 1995 Q2 | 400 Thousand USD | 300.0% |
| 1995 Q3 | 100 Thousand USD | -75.0% |
| 1995 FY | 400 Thousand USD | 300.0% |
| 1994 FY | 100 Thousand USD | 0.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 Q4 | 100 Thousand USD | 0.0% |
| 1993 FY | 100 Thousand USD | -50.0% |
| 1993 Q4 | 100 Thousand USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1992 Q4 | 100 Thousand USD | 0.0% |
| 1992 Q3 | 100 Thousand USD | -50.0% |
| 1992 Q2 | 200 Thousand USD | -33.33% |
| 1992 Q1 | 300 Thousand USD | 0.0% |
| 1992 FY | 200 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | -326.326% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1541.246% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 72.544% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 13.469% |
| Azitra, Inc. | 2.2 Million USD | -1670.662% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -941.004% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | -496.183% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | -113.63% |
| CEL-SCI Corporation | 17.31 Million USD | -125.236% |
| iBio, Inc. | 7.41 Million USD | -426.262% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | -450.065% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 15.834% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -211.596% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | -581.748% |
| NanoViricides, Inc. | 1.35 Million USD | -2769.936% |
| Oragenics, Inc. | 1.79 Million USD | -2068.636% |
| BiomX Inc. | 55.07 Million USD | 29.195% |
| BiomX Inc. | 55.07 Million USD | 29.195% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 23.334% |
| Palatin Technologies, Inc. | 10.85 Million USD | -259.286% |
| Scorpius Holdings, Inc. | 22.74 Million USD | -71.462% |